Edward Messing

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria
    Deep Trivedi
    Department of Urology, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, USA
    BMC Urol 9:13. 2009
  2. ncbi Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1
    Aimee M Johnson
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Elmwood Avenue, Rochester, New York, USA
    BMC Urol 8:7. 2008
  3. ncbi Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulator
    Hani H Rashid
    Department of Urology, University of Rochester, Rochester, New York, USA
    BMC Urol 4:3. 2004
  4. ncbi Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease
    Edward M Messing
    Department of Urology, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Clin Oncol 27:2443-9. 2009
  5. ncbi Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy
    Edward M Messing
    Department of Urology, University of Rochester, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA
    Urol Clin North Am 30:687-702, viii. 2003
  6. ncbi Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer
    Edward Messing
    University of Rochester, Rochester, New York 14642, USA
    J Urol 176:500-4. 2006
  7. ncbi Markers of detection
    Edward Messing
    Department of Urology, University of Rochester, Rochester, NY 14642, USA
    Urol Oncol 25:344-7. 2007
  8. ncbi Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States
    Edward M Messing
    Department of Urology, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Urol 174:1238-41. 2005
  9. ncbi Long-term outcome of hematuria home screening for bladder cancer in men
    Edward M Messing
    Department of Urology, University of Rochester, Rochester, New York 14642, USA
    Cancer 107:2173-9. 2006
  10. ncbi Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy
    Edward M Messing
    Department of Urology, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Lancet Oncol 7:472-9. 2006

Detail Information

Publications77

  1. ncbi Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria
    Deep Trivedi
    Department of Urology, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, USA
    BMC Urol 9:13. 2009
    ....
  2. ncbi Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1
    Aimee M Johnson
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Elmwood Avenue, Rochester, New York, USA
    BMC Urol 8:7. 2008
    ..Furthermore, because BC growth in UPII-SV40T mice is exophytic, we speculated BC growth was dependent on angiogenesis and angiogenesis was, in turn, androgen responsive...
  3. ncbi Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulator
    Hani H Rashid
    Department of Urology, University of Rochester, Rochester, New York, USA
    BMC Urol 4:3. 2004
    ..This study was performed to determine the effect of APF on the cell cycle of bladder epithelial cells so as to better understand its antiproliferative activity...
  4. ncbi Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease
    Edward M Messing
    Department of Urology, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Clin Oncol 27:2443-9. 2009
    ..Our goal was to determine whether presenting grade and stage of bladder cancer (BC), which directly affect disease-specific survival, also influence time to and cause of non-BC deaths...
  5. ncbi Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy
    Edward M Messing
    Department of Urology, University of Rochester, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA
    Urol Clin North Am 30:687-702, viii. 2003
    ..This article reviews the selection of patients for these noncurative approaches, strategies for clinical monitoring, the choices of intervention therapies upon progression, and when to start these therapies...
  6. ncbi Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer
    Edward Messing
    University of Rochester, Rochester, New York 14642, USA
    J Urol 176:500-4. 2006
    ..Ornithine decarboxylase catalyzes the rate limiting step in polyamine synthesis and its activity can be inhibited by difluoromethylornithine, which has been shown in preclinical studies, to prevent bladder cancer...
  7. ncbi Markers of detection
    Edward Messing
    Department of Urology, University of Rochester, Rochester, NY 14642, USA
    Urol Oncol 25:344-7. 2007
    ..However, markers may be useful for directing which patients age <or=40 with asymptomatic microhematuria without histories of smoking, particularly women, require cystoscopic evaluation...
  8. ncbi Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States
    Edward M Messing
    Department of Urology, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Urol 174:1238-41. 2005
    ..We assessed the performance of the ImmunoCyt immunocytochemical test for detecting bladder cancer recurrence in patients with prior superficial bladder cancers compared with cystoscopic and histological findings...
  9. ncbi Long-term outcome of hematuria home screening for bladder cancer in men
    Edward M Messing
    Department of Urology, University of Rochester, Rochester, New York 14642, USA
    Cancer 107:2173-9. 2006
    ....
  10. ncbi Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy
    Edward M Messing
    Department of Urology, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Lancet Oncol 7:472-9. 2006
    ....
  11. ncbi The timing of hormone therapy for men with asymptomatic advanced prostate cancer
    Edward Messing
    Department of Urology, University of Rochester, Rochester, NY 14642, USA
    Urol Oncol 21:245-54. 2003
    ..It is recommended that after an assessment of their disease risk, patients should be informed about the benefits and side effects of all potential treatment options and allowed to make an informed choice about their treatment...
  12. ncbi Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial
    Edward M Messing
    University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Clin Oncol 21:1214-22. 2003
    ..To evaluate the role of adjuvant interferon alfa after complete resection of locally extensive renal cell carcinoma...
  13. ncbi Robot-assisted prostate brachytherapy
    Yan Yu
    Department of Radiation Oncology, University of Rochester, Rochester, NY 14642, USA
    Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv 9:41-9. 2006
    ..Preliminary experimental results reveal that the prototype system is quite accurate (sub-millimeter) in placing brachytherapy needles...
  14. ncbi Hybrid dosimetry: feasibility of mixing angulated and parallel needles in planning prostate brachytherapy
    Lei Fu
    Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, New York 14642, USA
    Med Phys 33:1192-8. 2006
    ..When close to the breakdown point, the dosimetry outcomes worsen drastically. Therefore, for moderate PAI the hybrid dosimetry is feasible...
  15. ncbi Robot-assisted and laparoscopic partial nephrectomy with near infrared fluorescence imaging
    Scott Tobis
    Department of Urology, University of Rochester Medical Center, Rochester, New York, USA
    J Endourol 26:797-802. 2012
    ..The feasibility of a novel intraoperative imaging technique to differentiate tumor from surrounding parenchyma during laparoscopic and robot-assisted partial nephrectomy was evaluated...
  16. ncbi Surveillance for recurrent bladder cancer using a point-of-care proteomic assay
    H Barton Grossman
    Department of Urology, M. D. Anderson Cancer Center, Houston, Tex 77030, USA
    JAMA 295:299-305. 2006
    ..2%; 95% CI, 87.7%-97.8%; P = .08). CONCLUSION: The noninvasive point-of-care assay for elevated urinary NMP22 protein can increase the ability to detect recurrent bladder cancer, with test results available during the patient visit...
  17. ncbi Microscopic invasion of perivesical fat by urothelial carcinoma: implications for prognosis and pathology practice
    Emil Scosyrev
    Department of Community, Preventive Medicine, University of Rochester, Rochester, NY, USA
    Urology 76:908-13; discussion 914. 2010
    ....
  18. ncbi Vivo motion and force measurement of surgical needle intervention during prostate brachytherapy
    Tarun Podder
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Med Phys 33:2915-22. 2006
    ..The knowledge gleaned from this study promises to be useful for not only designing mechanical/robotic systems but also developing a predictive deformation model of the prostate and real-time adaptive controlling of the needle...
  19. ncbi Bouquet brachytherapy: feasibility and optimization of conically spaced implants
    Lei Fu
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642-8647, USA
    Brachytherapy 4:59-63. 2005
    ..CONCLUSIONS: Conically spaced implantation for prostate brachytherapy with 125I and 103Pd seeds is feasible in terms of dosimetry outcomes. Techniques for optimized inverse planning for this approach have been developed...
  20. ncbi Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection
    Yair Lotan
    Department of Urology, University of Texas, Southwestern Medical Center, Dallas, TX 75390, USA
    BJU Int 101:1362-7. 2008
    ..Newton, MA, USA) for the detection of bladder cancer, as this is a point-of-care assay that measures NMPs in voided urine...
  21. ncbi Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies
    Emil Scosyrev
    Department of Urology, University of Rochester Medical Center, Rochester, NY, USA
    BJU Int 111:E71-7. 2013
    ..However, there was considerable disagreement between individual studies in reported findings and conclusions...
  22. ncbi Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview
    Emil Scosyrev
    Department of Community and Preventive Medicine, University of Rochester, Rochester, NY 14642, USA
    Urol Oncol 30:126-32. 2012
    ....
  23. ncbi The burden of bladder cancer in men and women: analysis of the years of life lost
    Emil Scosyrev
    Department of Urology, University of Rochester Medical Center, Rochester, NY, USA
    BJU Int 109:57-62. 2012
    ..To estimate the average loss in life expectancy (LE) due to bladder cancer (BC) in men and women in the USA...
  24. ncbi Is there a favorable subset of patients with prostate cancer who develop oligometastases?
    Deepinder Singh
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642 8647, USA
    Int J Radiat Oncol Biol Phys 58:3-10. 2004
    ....
  25. ncbi Androgen deprivation therapy for prostate cancer: current status and future prospects
    Hiroshi Miyamoto
    George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and the Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
    Prostate 61:332-53. 2004
    ..In order to improve overall survival, novel treatment strategies that prolong the androgen-dependent state and that are useful for androgen-independent disease based on specific molecular mechanisms need to be identified...
  26. ncbi Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system
    Emil Scosyrev
    Department of Urology, University of Rochester Medical Center, NY, USA
    BJU Int 110:1485-90. 2012
    ..To examine the frequency of PSA testing in men aged ≥75 years before and after the 2008 US Preventive Services Task Force (USPSTF) recommendation to stop prostate-specific antigen (PSA) screening at age 75...
  27. ncbi Near infrared fluorescence imaging after intravenous indocyanine green: initial clinical experience with open partial nephrectomy for renal cortical tumors
    Scott Tobis
    Department of Urology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Urology 79:958-64. 2012
    ....
  28. ncbi A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D
    Huei Ju Ting
    Department of Urology, University of Rochester, Rochester, New York, USA
    Cancer Res 72:958-68. 2012
    ..Together, our findings identify a novel vitamin D-mediated chemopreventive mechanism involving a positive feedback loop between the DNA repair proteins ATM and VDR...
  29. ncbi Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, MC 7845, 7703 Floyd Curl Dr, San Antonio, TX 78229 3900, USA
    JAMA 296:2329-35. 2006
    ..However, the optimal management of these patients after radical prostatectomy is unknown...
  30. ncbi Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment?
    Emil Scosyrev
    Department of Community and Preventive Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Urology 73:822-7. 2009
    ..To determine whether the survival of patients with squamous cell carcinoma (SCC) is different from that of patients with urothelial carcinoma, after adjusting for stage, grade, demographic factors, and the initial treatment...
  31. ncbi Quantitative characterization of viscoelastic properties of human prostate correlated with histology
    Man Zhang
    Department of Biomedical Engineering, University of Rochester, Rochester, NY 14627, USA
    Ultrasound Med Biol 34:1033-42. 2008
    ..01). This study contributes to the current limited knowledge on the viscoelastic properties of the human prostate, and the inherent elastic contrast produced by cancer...
  32. ncbi Androgen deprivation therapy for prostate cancer
    Eric A Singer
    Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Expert Opin Pharmacother 9:211-28. 2008
    ....
  33. ncbi Long-term outcome of home dipstick testing for hematuria
    Ralph Madeb
    Department of Urology, Strong Memorial Hospital, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA
    World J Urol 26:19-24. 2008
    ..8 years. The lower overall mortality in screenees with BC was primarily because of the reduced mortality from BC in that group. Screening had effected a shift of the high grade tumors to earlier (more superficial) stages at diagnosis...
  34. ncbi Chemoprevention of bladder cancer
    Dragan J Golijanin
    Urology Department, University of Rochester Medical Center, 601 Elmwood Avenue, P.O. Box 656, Rochester, NY 14642, USA
    World J Urol 24:445-72. 2006
  35. ncbi Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors
    Ralph Madeb
    Department of Urology, University of Rochester School of Medicine, Rochester, New York, USA
    Cancer 115:2660-70. 2009
    ..The authors sought to determine whether US urologists have adopted this practice, and its potential effect on costs of bladder cancer (BC) care...
  36. ncbi Initial observations of reduced uroflow in transgenic adenocarcinoma of murine prostate
    Ronald W Wood
    Department of Urology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642 8668, USA
    Urology 67:1324-8. 2006
    ..Spontaneous death from urinary outlet obstruction occurs in the TRAMP mouse...
  37. ncbi CT in detecting urinary tract calculi: influence on patient imaging and clinical outcomes
    Ronald H Gottlieb
    Dept of Radiology, Univ of Rochester Medical Ctr, NY 14642, USA
    Radiology 225:441-9. 2002
    ....
  38. ncbi Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
    Hiroshi Miyamoto
    Department of Pathology, University of Rochester Medical Center, NY 14642, USA
    Nat Clin Pract Oncol 2:236-7. 2005
  39. ncbi Detection of bladder cancer using a point-of-care proteomic assay
    H Barton Grossman
    Department of Urology, M D Anderson Cancer Center, Houston, Tex 77030, USA
    JAMA 293:810-6. 2005
    ..Urine tests are frequently part of an evaluation, but have either been nonspecific for cancer or required specialized analysis at a laboratory...
  40. ncbi Sex and racial differences in bladder cancer presentation and mortality in the US
    Emil Scosyrev
    Department of Community and Preventive Medicine, University of Rochester, Rochester, New York 14642, USA
    Cancer 115:68-74. 2009
    ....
  41. ncbi Transrectal sonography in prostate evaluation
    Judd Boczko
    Department of Urology, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
    Radiol Clin North Am 44:679-87, viii. 2006
    ..This article review the indications and principles of TRUS of the prostate, the technique of TRUS, and controversies pertaining to prostate core biopsy...
  42. ncbi Female bladder cancer: incidence, treatment, and outcome
    Emil Scosyrev
    Department of Community and Preventive Medicine, University of Rochester, Rochester, New York, USA
    Curr Opin Urol 20:404-8. 2010
    ..In this review, we describe our current understanding of the relationship between sex and bladder cancer incidence and outcomes and discuss the most recent developments in this area of research...
  43. ncbi Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
    Vinata B Lokeshwar
    Department of Urology, University of Miami, Miami, Florida 33101, USA
    Urology 66:35-63. 2005
    ..Therefore, use of bladder tumor markers in the management of patients with bladder cancer will require the willingness of both urologists and clinicians to accept them...
  44. ncbi Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Eric A Singer
    Department of Urology, University of Rochester Medical Center, Rochester, New York USA
    Can J Urol 15:4381-7. 2008
    ..Additionally, strategies for addressing each of these escape mechanisms, which may be able to prolong responsiveness to ADT, will be discussed...
  45. ncbi Early versus late hormonal therapy for prostate cancer
    Hiroshi Miyamoto
    Department of Urology, University of Rochester, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA
    Curr Urol Rep 5:188-96. 2004
    ....
  46. ncbi Timing hormonal therapy in prostate cancer
    Annette E Sessions
    Department of Urology, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Urol Clin North Am 29:223-7, xi. 2002
    ..Studies have pointed to the benefits of initiating androgen ablation therapy earlier in the treatment of prostate cancer; the greatest benefits of anti-androgen therapy may be gained when only tiny amounts of prostate cancer are present...
  47. ncbi Controversies surrounding lymph node dissection for prostate cancer
    Ganesh S Palapattu
    Department of Urology, The Methodist Hospital, 6560 Fannin, Suite 2100, Houston, TX 77030, USA
    Urol Clin North Am 37:57-65, Table of Contents. 2010
    ..The lack of robust randomized clinical trials in the literature necessitates a careful analysis of retrospective and case series data...
  48. ncbi Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer
    Manish Kohli
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Cancer Biomark 7:101-8. 2010
    ..An association of a single nucleotide polymorphism (SNP) of the KLK2 gene (rs198977; c.748C>T; R250W) with risk for developing prostate cancer has been observed. We evaluated the role of R250W SNP for prognosis in prostate cancer...
  49. ncbi Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness
    Huei Ju Ting
    Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA
    Mol Cancer Res 5:967-80. 2007
    ....
  50. ncbi Uroflow in murine urethritis
    Yuk-Yuen Max Leung
    Department of Urology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642-8668, USA
    Urology 64:378-82. 2004
    ..Murine urethritis can be differentiated from cystitis, known to be associated with a decrease in voided volume. The observed changes were consistent with urethral obstruction induced by local swelling and inflammation...
  51. ncbi Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin
    Jason R Gee
    Department of Urology, School of Medicine and Public Health, University of Wisconsin Madison, Madison, WI 53792, USA
    BJU Int 103:736-9. 2009
    ....
  52. ncbi Grade progression and regression in recurrent urothelial cancer
    Ali Borhan
    Department of Urology, University of Rochester, Rochester, New York 14642, USA
    J Urol 169:2106-9. 2003
    ..The loss of p53 positivity in regressing tumors indicates that these recurrences are molecularly distinct from the corresponding initial tumor...
  53. ncbi Androgen receptor is a tumor suppressor and proliferator in prostate cancer
    Yuanjie Niu
    George Whipple Lab for Cancer Research, Department of Pathology, University of Rochester Medical Center, Rochester, NY 14620, USA
    Proc Natl Acad Sci U S A 105:12182-7. 2008
    ..Collectively, our understanding of these opposing roles of prostatic AR may revolutionize the way we combat prostate cancer, and allow the development of new and better therapies by targeting only the proliferative role of AR...
  54. ncbi Decreased bladder cancer growth in parous mice
    Aimee M Johnson
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Urology 72:470-3. 2008
    ..To investigate the association between parity and exophytic bladder cancer growth in the UPII-SV40T transgenic mouse model of bladder cancer...
  55. ncbi Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors
    Terrence L Fisher
    Department of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochester Cancer Center, 575 Elmwood Avenue, Rochester, NY 14642, USA
    Prostate 51:153-65. 2002
    ..CONCLUSIONS: These hK2-specific antibodies illustrate a novel approach for constructing B-cell hybridomas and provide useful reagents to examine the role of hK2 in the biology and detection of prostate cancer...
  56. ncbi A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients
    Edward Messing
    University of Rochester Medical Center, Rochester, New York, USA
    Cancer Prev Res (Phila) 5:621-30. 2012
    ..Genistein displayed a possible bimodal effect (more effective at the lower dose) on bladder cancer tissue EGFR phosphorylation that should be evaluated further, possibly in combination with other agents...
  57. ncbi Lost and now found: retained straight catheter for 20 years
    Emma Ester Bendaña
    University of Rochester Medical Center, Rochester, NY 14642, USA
    Urology 77:73-4. 2011
    ..A Foley catheter was inserted easily into the urethra for drainage. At last follow-up, 7 weeks after surgery, the patient was voiding successfully without any difficulties...
  58. ncbi Automatic localization of implanted seeds from post-implant CT images
    Haisong Liu
    Department of Radiation Oncology, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Phys Med Biol 48:1191-203. 2003
    ..It is reliable and convenient for localizing implanted seeds on CT and can be used to assist post-implant dosimetry for prostate brachytherapy...
  59. ncbi Down-regulation of NF-kappaB signals is involved in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness
    Bo Ying Bao
    Department of Urology and Pathology and Laboratory Medicine, Rochester, NY 14642, USA
    J Steroid Biochem Mol Biol 120:11-21. 2010
    ..Together, we conclude that NF-kappaB signaling is critical for vitamin D sensitivity, and dysregulation of this pathway would result in vitamin D resistance and disease progression...
  60. ncbi Long-term outcome of patients with a negative work-up for asymptomatic microhematuria
    Ralph Madeb
    Department of Urology, University of Rochester School of Medicine, Rochester, New York, USA
    Urology 75:20-5. 2010
    ....
  61. ncbi Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells
    Yi-Fen Lee
    George Whipple Laboratory for Cancer Research, Department of Pathology, and the Cancer Center, University of Rochester Medical Center, New York 14642, USA
    Cancer Res 62:6039-44. 2002
    ..This raises a concern for using HF in the complete-androgen-ablation therapy in prostate cancer treatment and provides a possible pathway that might contribute to the HF withdrawal syndrome...
  62. ncbi Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer
    Hiroshi Miyamoto
    Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Mol Carcinog 44:1-10. 2005
    ..We hypothesize that androgen deprivation, in combination with inhibition of the Akt, COX-2, and MMP-9 pathways, delays the androgen-independent transition and has more beneficial effects than hormonal therapy alone...
  63. ncbi Prostate cancer: three-dimensional sonoelastography for in vitro detection
    Lawrence S Taylor
    Department of Biomedical Engineering, University of Rochester, 240 Hutchison Rd, Rm 205, Rochester, NY 14627-0126, USA
    Radiology 237:981-5. 2005
    ..CONCLUSION: Sonoelastography performed considerably better than did gray-scale US in the depiction of prostate cancer for tumors with volumes of more than 1 cm3...
  64. ncbi Promotion of bladder cancer development and progression by androgen receptor signals
    Hiroshi Miyamoto
    Department of Pathology, University of Rochester Medical Center, 601 Elmwood Ave, Box 626, Rochester, NY 14642, USA
    J Natl Cancer Inst 99:558-68. 2007
    ..Unlike prostate cancer, human bladder cancer is not generally considered to be dependent on hormone activity. We investigated the possible involvement of androgens and the androgen receptor (AR) in bladder cancer...
  65. ncbi Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas
    Xi Na
    Department of Urology, University of Rochester Medical Center, New York 14642, USA
    J Urol 170:588-92. 2003
    ..0001). CONCLUSIONS: Our findings indicate that VHL gene alterations and HIF-1 alpha protein expression correlate with a significant increase in VEGF production by RCC. In turn it is associated with a more aggressive tumor phenotype...
  66. ncbi Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein
    Xi Na
    Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA
    EMBO J 22:4249-59. 2003
    ..Together, our results suggest that hsRPB7 is a downstream target of the VHL ubiquitylating complex and pVHL may regulate angiogenesis by targeting hsRPB7 for degradation via the ubiquitylation pathway and preventing VEGF expression...
  67. ncbi A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis
    Robert Mayer
    University of Rochester, Rochester, New York, USA
    J Urol 173:1186-91. 2005
    ..CONCLUSIONS: Although the BCG safety profile was acceptable, the response rate for the primary outcome was low. Effective medical treatment for patients with moderate to severe interstitial cystitis remains elusive...
  68. ncbi Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells
    Yu Zhang
    Department of Urology, University of Rochester, Rochester, NY 14642, USA
    Proc Natl Acad Sci U S A 99:7408-13. 2002
    ..This previously undescribed mechanism may explain how VES inhibits the growth of prostate cancer cells and help us to establish new therapeutic concepts for the prevention and treatment of prostate cancer...
  69. ncbi Early detection and measurement of urothelial tumors in mice
    Aimee M Johnson
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Urology 67:1309-14. 2006
    ..This approach could provide an important alternative to serial sacrifice experimental designs, while refining statistical power and reducing animal use...
  70. ncbi Current state of screening for bladder cancer
    Ralph Madeb
    University of Rochester School of Medicine, Department of Urology, Rochester, NY, USA
    Expert Rev Anticancer Ther 7:981-7. 2007
    ..This special report reviews the current state of bladder cancer screening in the USA...
  71. ncbi Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice
    Ming Chen
    Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, New York 14642, USA
    Endocrinology 150:251-9. 2009
    ....
  72. ncbi Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway
    Jing Ni
    Department of Urology, University of Rochester, Rochester, New York, USA
    Cancer Res 65:9807-16. 2005
    ..Therefore, TAP may represent a new prognostic marker for prostate cancer progression...
  73. ncbi Gender, racial and age differences in bladder cancer incidence and mortality
    Ralph Madeb
    Department of Urology, Strong Memorial Hospital University of Rochester Medical Center, NY, USA
    Urol Oncol 22:86-92. 2004
    ..In this manuscript we review the current literature and epidemiological studies on the affects of gender, race and age on incidence and mortality of bladder cancer...
  74. ncbi Continuous bladder infusion methods for studying voiding function in the ambulatory mouse
    Annette Sessions
    Department of Urology, University of Rochester School of Medicine, Rochester, New York 14642-8668, USA
    Urology 60:707-13. 2002
    ..When used in combination with counterbalanced swivel assemblies and electronic balance technology, these methods permit prolonged evaluation of micturition patterns in the awake, ambulatory mouse...
  75. ncbi Node positive renal cell cancer. Who can be helped?
    Edward M Messing
    Eur Urol 51:1477-8. 2007
  76. ncbi Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
    Edward M Messing
    J Urol 170:1955; author reply 1955-6. 2003
  77. ncbi Bladder tumor markers
    Edward M Messing
    J Urol 175:1195-6. 2006